02.24.25 -- 7 Focus Areas To Establish A Win-Win Relationship With Your CDMO

A high-performance, helper virus-free stable producer cell line is derived from proprietary high-producer HEK293 cells and is cultivated in a chemically defined, serum-free, ADCF medium in suspension.

Advanced therapies present challenges when it comes to scaling up production. Explore how collaboration, investment in R&D, and process optimization are paving the way for new treatment options.

Learn to leverage cutting-edge technologies and innovative processes to enhance yields, quality, and scalability for next-generation gene therapy development and delivery.

By refining variables such as starting DNA, reagents, cell density, and media composition, organizations can improve rAAV process efficiency and scalability.

Ensure the safe, compliant, and seamless delivery of gene therapies by leveraging advanced logistics solutions designed to meet stringent regulatory standards and mitigate risk at every stage.

Gene therapy offers hope for rare genetic diseases, with advancements in polymer nanoparticles addressing delivery challenges and paving the way for innovative, effective treatments.

Discover a new potency bioassay using RT-qPCR to assess relative transcription activity, and learn more about the advantages and limitations of transcriptional assays versus reporter gene assays.

Ensure the safety and efficacy of lentiviral-based therapies by addressing the risks of replication-competent lentiviruses (RCLs) through advanced monitoring and control strategies.

Scaling up viral vector production can be challenging, and ensuring consistent titers and activity requires careful optimization and technical expertise.

This study evaluates filter trains from four vendors, aiming to enhance titer recovery, HCP removal, DNA breakthrough, turbidity reduction, and throughput in gene therapy manufacturing.